The latest price reference summary of Mobotinib (Mobosetinib) in 2025

Mobocertinib is a targeted drug used to treat non-small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) mutations. The drug is already on the market in China, but due to its high price and not yet being included in medical insurance, patients may encounter some difficulties in purchasing it through formal channels. At present, patients mainly purchase it through hospital pharmacies, and specific prices need to be consulted based on local conditions.

In China, the original drug of Mobotinib is mainly produced by the Hong Kong version and the Japanese Takeda version. The prices of these original drugs are generally relatively high, usually around 7,000 to 8,000 RMB. These versions of mobotinib can provide highly effective treatment, but due to their high price, may be a significant financial burden for some patients. Especially if it is not covered by medical insurance, patients may need to pay the full price at the time of purchase.

In comparison, the generic version of Mobotinib is more affordable. The Lao version of the generic version of Mobotinib is a more common choice, and its price is about 3,000 yuan, which is much lower than the price of the original drug. This allows some patients to obtain the drug in a more economical way. Although generic drugs and original drugs are basically the same in terms of drug ingredients, patients still need to pay attention to the source and quality of the drug when choosing to ensure that they choose compliant and safe drugs.

For drugs that have not been included in medical insurance, patients can obtain them through some international channels, such as through cross-border e-commerce or ordering directly from overseas drug suppliers. With the update of drug prices in 2025, the price fluctuation of mobotinib may be affected by supply chain, exchange rate and other factors. Therefore, patients should pay attention to price changes regularly to make a reasonable choice when needed. At the same time, patients should also communicate with doctors and pharmacists to choose the most suitable medicine and purchase method.

References：https://en.wikipedia.org/wiki/Mobocertinib